Importer of Controlled Substances Application: Experic LLC, 93340-93341 [2024-27673]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
93340
Federal Register / Vol. 89, No. 228 / Tuesday, November 26, 2024 / Notices
Commission’s Rules of Practice and
Procedure, part 201, subparts A and B
(19 CFR part 201), and part 207,
subparts A and C (19 CFR part 207).
Participation in the investigations and
public service list.—Persons, including
industrial users of the subject
merchandise and, if the merchandise is
sold at the retail level, representative
consumer organizations, wishing to
participate in the final phase of these
investigations as parties must file an
entry of appearance with the Secretary
to the Commission, as provided in
§ 201.11 of the Commission’s rules, no
later than 21 days prior to the hearing
date specified in this notice. A party
that filed a notice of appearance during
the preliminary phase of the
investigations need not file an
additional notice of appearance during
this final phase. The Secretary will
maintain a public service list containing
the names and addresses of all persons,
or their representatives, who are parties
to the investigations.
Please note the Secretary’s Office will
accept only electronic filings during this
time. Filings must be made through the
Commission’s Electronic Document
Information System (EDIS, https://
edis.usitc.gov). No in-person paperbased filings or paper copies of any
electronic filings will be accepted until
further notice.
Limited disclosure of business
proprietary information (BPI) under an
administrative protective order (APO)
and BPI service list.—Pursuant to
§ 207.7(a) of the Commission’s rules, the
Secretary will make BPI gathered in the
final phase of these investigations
available to authorized applicants under
the APO issued in the investigations,
provided that the application is made
no later than 21 days prior to the
hearing date specified in this notice.
Authorized applicants must represent
interested parties, as defined by 19
U.S.C. 1677(9), who are parties to the
investigations. A party granted access to
BPI in the preliminary phase of the
investigations need not reapply for such
access. A separate service list will be
maintained by the Secretary for those
parties authorized to receive BPI under
the APO.
Staff report.—The prehearing staff
report in the final phase of these
investigations will be placed in the
nonpublic record on March 19, 2025,
and a public version will be issued
thereafter, pursuant to § 207.22 of the
Commission’s rules.
Hearing.—The Commission will hold
a hearing in connection with the final
phase of these investigations beginning
at 9:30 a.m. on Tuesday, April 1, 2025.
Requests to appear at the hearing should
VerDate Sep<11>2014
18:03 Nov 25, 2024
Jkt 265001
be filed in writing with the Secretary to
the Commission on or before Thursday,
March 27, 2025. Any requests to appear
as a witness via videoconference must
be included with your request to appear.
Requests to appear via videoconference
must include a statement explaining
why the witness cannot appear in
person; the Chairman, or other person
designated to conduct the
investigations, may in their discretion
for good cause shown, grant such a
request. Requests to appear as remote
witness due to illness or a positive
COVID–19 test result may be submitted
by 3:00 p.m. the business day prior to
the hearing. Further information about
participation in the hearing will be
posted on the Commission’s website at
https://www.usitc.gov/calendarpad/
calendar.html.
A nonparty who has testimony that
may aid the Commission’s deliberations
may request permission to present a
short statement at the hearing. All
parties and nonparties desiring to
appear at the hearing and make oral
presentations should attend a
prehearing conference, if deemed
necessary, to be held at 9:30 a.m. on
Friday, March 28, 2025. Parties shall file
and serve written testimony and
presentation slides in connection with
their presentation at the hearing by no
later than noon on March 31, 2025. Oral
testimony and written materials to be
submitted at the public hearing are
governed by sections 201.6(b)(2),
201.13(f), and 207.24 of the
Commission’s rules. Parties must submit
any request to present a portion of their
hearing testimony in camera no later
than 7 business days prior to the date of
the hearing.
Written submissions.—Each party
who is an interested party shall submit
a prehearing brief to the Commission.
Prehearing briefs must conform with the
provisions of § 207.23 of the
Commission’s rules; the deadline for
filing is March 26, 2025. Parties shall
also file written testimony in connection
with their presentation at the hearing,
and posthearing briefs, which must
conform with the provisions of § 207.25
of the Commission’s rules. The deadline
for filing posthearing briefs is April 8,
2025. In addition, any person who has
not entered an appearance as a party to
the investigations may submit a written
statement of information pertinent to
the subject of the investigations,
including statements of support or
opposition to the petition, on or before
April 8, 2025. On April 23, 2025, the
Commission will make available to
parties all information on which they
have not had an opportunity to
comment. Parties may submit final
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
comments on this information on or
before April 25, 2025, but such final
comments must not contain new factual
information and must otherwise comply
with § 207.30 of the Commission’s rules.
All written submissions must conform
with the provisions of § 201.8 of the
Commission’s rules; any submissions
that contain BPI must also conform with
the requirements of §§ 201.6, 207.3, and
207.7 of the Commission’s rules. The
Commission’s Handbook on Filing
Procedures, available on the
Commission’s website at https://
www.usitc.gov/documents/handbook_
on_filing_procedures.pdf, elaborates
upon the Commission’s procedures with
respect to filings.
Additional written submissions to the
Commission, including requests
pursuant to § 201.12 of the
Commission’s rules, shall not be
accepted unless good cause is shown for
accepting such submissions, or unless
the submission is pursuant to a specific
request by a Commissioner or
Commission staff.
In accordance with §§ 201.16(c) and
207.3 of the Commission’s rules, each
document filed by a party to the
investigations must be served on all
other parties to the investigations (as
identified by either the public or BPI
service list), and a certificate of service
must be timely filed. The Secretary will
not accept a document for filing without
a certificate of service.
Authority: These investigations are
being conducted under authority of title
VII of the Tariff Act of 1930; this notice
is published pursuant to § 207.21 of the
Commission’s rules.
By order of the Commission.
Issued: November 20, 2024.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2024–27687 Filed 11–25–24; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1456]
Importer of Controlled Substances
Application: Experic LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Experic LLC to be registered
as an importer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
SUMMARY:
E:\FR\FM\26NON1.SGM
26NON1
93341
Federal Register / Vol. 89, No. 228 / Tuesday, November 26, 2024 / Notices
Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before December 26, 2024. Such
persons may also file a written request
for a hearing on the application on or
before December 26, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
DATES:
is notice that on October 17, 2024,
Experic LLC, 2 Clarke Drive, Cranbury,
New Jersey 08512–3619, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
Controlled substance
Drug code
Nabilone ............
7379
Schedule
II
The company plans to import drug
code Nabilone (7379) for clinical trial
purposes. No other activity for this drug
code is authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2024–27673 Filed 11–25–24; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1453]
Bulk Manufacturer of Controlled
Substances Application: Cayman
Chemical Company
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Cayman Chemical Company
has applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
Supplementary Information listed below
for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before January 27, 2025. Such
persons may also file a written request
for a hearing on the application on or
before January 27, 2025.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on August 8, 2024,
Cayman Chemical Company, 1180 East
Ellsworth Road, Ann Arbor, Michigan
48108–2419, applied to be registered as
a bulk manufacturer of the following
basic class(es) of controlled
substance(s):
SUMMARY:
lotter on DSK11XQN23PROD with NOTICES1
Controlled substance
Drug code
3-Fluoro-N-methylcathinone (3-FMC) ........................................................................................................................
Cathinone ..................................................................................................................................................................
Methcathinone ...........................................................................................................................................................
4-Fluoro-N-methylcathinone (4-FMC) 1238 I N ........................................................................................................
Para-Methoxymethamphetamine (PMMA), 1-(4-methoxyphenyl)-N-methylpropan-2-amine ....................................
Pentedrone (a-methylaminovalerophenone) .............................................................................................................
Mephedrone (4-Methyl-N-methylcathinone) ..............................................................................................................
4-Methyl-N-ethylcathinone (4-MEC) ..........................................................................................................................
Naphyrone .................................................................................................................................................................
3-methylmethcathinone (2-(methylamino)-1-(3-methylphenyl)propan-1-one) ...........................................................
N-Ethylamphetamine .................................................................................................................................................
Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine) 1478 I N .................................................................
N,N-Dimethylamphetamine ........................................................................................................................................
Fenethylline ...............................................................................................................................................................
Aminorex ....................................................................................................................................................................
4-Methylaminorex (cis isomer) ..................................................................................................................................
4,4′-Dimethylaminorex (4,4′-DMAR; 4,5-dihydro-4-1595 I N methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine).
Gamma Hydroxybutyric Acid .....................................................................................................................................
Methaqualone ............................................................................................................................................................
Mecloqualone ............................................................................................................................................................
Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6Hthieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine ...........................
Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4Hbenzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine) ......................
VerDate Sep<11>2014
18:03 Nov 25, 2024
Jkt 265001
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
E:\FR\FM\26NON1.SGM
26NON1
Schedule
1233
1235
1237
1238
1245
1246
1248
1249
1258
1259
1475
1478
1480
1503
1585
1590
1595
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
2010
2565
2572
2780
2785
I
I
I
I
I
]]>Agencies
[Federal Register Volume 89, Number 228 (Tuesday, November 26, 2024)]
[Notices]
[Pages 93340-93341]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-27673]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1456]
Importer of Controlled Substances Application: Experic LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Experic LLC to be registered as an importer of basic class(es)
of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed
below for further drug information.
[[Page 93341]]
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants, therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
December 26, 2024. Such persons may also file a written request for a
hearing on the application on or before December 26, 2024.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment. All
requests for a hearing must be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: Drug Enforcement Administration, Attn: Administrator, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on October 17, 2024, Experic LLC, 2 Clarke Drive,
Cranbury, New Jersey 08512-3619, applied to be registered as an
importer of the following basic class(es) of controlled substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Nabilone............................ 7379 II
------------------------------------------------------------------------
The company plans to import drug code Nabilone (7379) for clinical
trial purposes. No other activity for this drug code is authorized for
this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2024-27673 Filed 11-25-24; 8:45 am]
BILLING CODE 4410-09-P
